COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN SPAIN

被引：1
|
作者：
Schweikert, B. [1 ]
Storck, C. T. [1 ]
Nunez, M. [2 ]
Dilla, T. [3 ]
Hartz, S. [4 ]
Sapin, C. [5 ]
机构：
[1] ICON, Munich, Germany
[2] Eli Lilly & Co, Alcobendas, Spain
[3] Lilly Spain, Madrid, Spain
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Eli Lilly & Co, Neuilly Sur Seine, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1902
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU66
引用
收藏
页码：S319 / S319
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Protsenko, M.
    Serpik, V
    VALUE IN HEALTH, 2019, 22 : S905 - S905
  • [42] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [43] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [44] COST-EFFECTIVENESS OF SEQUENCES OF BIOLOGIC TREATMENTS FOR MODERATE-TO-SEVERE PSORIASIS IN FINLAND
    Asseburg, C.
    Valgardsson, S.
    Soini, E. J.
    VALUE IN HEALTH, 2013, 16 (07) : A507 - A508
  • [45] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [46] Drug cost per responder for the treatment of moderate-to-severe psoriasis and active psoriatic arthritis
    Armstrong, April
    Merola, Joseph
    Yang, Min
    Li, Junlong
    Zhao, Jing
    Sundaram, Murali
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB105 - AB105
  • [47] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
    Klimes, J.
    Mollon, P.
    Graham, C.
    Rajnoch, J.
    Dostal, F.
    Skalicky, D.
    Jordan, P.
    Depta, J.
    VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [48] Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Boni E. Elewski
    Andrew Blauvelt
    Gaia Gallo
    Eric Wolf
    Missy McKean-Matthews
    Russel Burge
    Joseph F. Merola
    Alice B. Gottlieb
    Lyn C. Guenther
    Dermatology and Therapy, 2022, 12 : 911 - 920
  • [49] Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Elewski, Boni E.
    Blauvelt, Andrew
    Gallo, Gaia
    Wolf, Eric
    McKean-Matthews, Missy
    Burge, Russel
    Merola, Joseph F.
    Gottlieb, Alice B.
    Guenther, Lyn C.
    DERMATOLOGY AND THERAPY, 2022, 12 (04) : 911 - 920
  • [50] SECUKINUMAB REDUCES HSCRP LEVELS IN SUBJECTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND CONCOMITANT PSORIATIC ARTHRITIS: A SUB-ANALYSIS FROM THE PHASE 3 ERASURE STUDY
    Gottlieb, A.
    Sigurgeirsson, B.
    Blauvelt, A.
    Gong, Y.
    Papavassilis, C.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1047 - 1048
12345